IgA肾病免疫抑制治疗的研究进展
Advances in Immunosuppressive Therapy for IgA Nephropathy
DOI: 10.12677/tcm.2026.153145, PDF,    科研立项经费支持
作者: 孙 晶：黑龙江中医药大学附属第一医院第一临床医学院，黑龙江 哈尔滨；黑龙江省中医药科学院研究生院，黑龙江 哈尔滨；代培方：黑龙江中医药大学附属第一医院第一临床医学院，黑龙江 哈尔滨；张冠珣：黑龙江中医药大学第二临床医学院，黑龙江 哈尔滨；刘遂学, 张福利*：黑龙江中医药大学基础医学院，黑龙江 哈尔滨；罗世菲：重庆市中医院规培办公室，重庆
关键词: IgA肾病；免疫抑制治疗；研究进展；IgA Nephropathy； Immunosuppressive Therapy； Research Progress
摘要: IgA肾病(IgAN)是半乳糖缺陷型IgA1 (Gd-IgA1)沉积引发免疫炎症的疾病。其发病机制尚未完全明确，免疫抑制治疗是延缓疾病发生、进展的关键。本文综述IgAN临床治疗中常用的传统免疫抑制剂及新型免疫调节剂，包括糖皮质激素、霉酚酸酯、钙调磷酸酶抑制、靶向补体药物及B细胞靶向药物，并对个体化用药方案进行探讨。聚焦免疫抑制剂治疗前沿，结合“多重打击”机制，为IgAN个体化精准免疫抑制治疗提供理论与临床参考。
Abstract: IgA nephropathy (IgAN) is a disease characterized by immune inflammation triggered by the deposition of galactose-deficient IgA1 (Gd-IgA1). Its pathogenesis has not been fully elucidated, and immunosuppressive therapy is the key to delaying the onset and progression of the disease. This paper reviews the conventional immunosuppressants and novel immunomodulators commonly used in the clinical treatment of IgAN, including glucocorticoids, mycophenolate mofetil, calcineurin inhibitors, targeted complement drugs and B-cell targeted drugs, and discusses the individualized medication regimens. By focusing on the cutting-edge research of immunosuppressive therapy and combining with the “multi-hit” mechanism, this review provides theoretical and clinical references for individualized and precise immunosuppressive therapy for IgAN.
文章引用：孙晶, 代培方, 张冠珣, 刘遂学, 罗世菲, 张福利. IgA肾病免疫抑制治疗的研究进展[J]. 中医学, 2026, 15(3): 135-141. https://doi.org/10.12677/tcm.2026.153145

参考文献

[1] Knoppova, B., Reily, C., King, R.G., Julian, B.A., Novak, J. and Green, T.J. (2021) Pathogenesis of IgA Nephropathy: Current Understanding and Implications for Development of Disease-Specific Treatment. Journal of Clinical Medicine, 10, Article No. 4501. [Google Scholar] [CrossRef] [PubMed]
[2] Du, Y., Cheng, T., Liu, C., Zhu, T., Guo, C., Li, S., et al. (2023) IgA Nephropathy: Current Understanding and Perspectives on Pathogenesis and Targeted Treatment. Diagnostics, 13, Article No. 303. [Google Scholar] [CrossRef] [PubMed]
[3] 黄娜娅, 文琼, 谭丽, 等. 改善全球肾脏病预后组织2025年IgA肾病管理临床实践指南解读[J]. 中华肾脏病杂志, 2025, 41(12): 1042-1048.
[4] 梁婷玉, 杨华, 冯真, 等. IgA肾病患者肾小球中糖皮质激素受体表达与治疗反应性的临床研究[J]. 中国中西医结合肾病杂志, 2023, 24(6): 502-505.
[5] 钟永忠, 费丹, 林宜, 等. 基于真实世界回顾性分析糖皮质激素干预IgA肾病的临床研究[J]. 中国中西医结合肾病杂志, 2023, 24(3): 213-217.
[6] 东方月花. 应用糖皮质激素治疗IgA肾病的观察及评估[J]. 临床医药文献电子杂志, 2020, 7(36): 150.
[7] 刘开翔, 龚蓉, 冯杰, 等. 单纯糖皮质激素治疗IgA肾病的系统评价[J]. 中国中西医结合肾病杂志, 2020, 21(4): 321-327.
[8] 皮明婧, 袁静, 刘璐, 等. 糖皮质激素治疗IgA肾病: 来自IgA肾病激素治疗评估的全球研究临床试验的经验[J]. 临床肾脏病杂志, 2024, 24(5): 406-411.
[9] 鲜美玲, 李春燕, 吴鹏, 等. 糖皮质激素在药物性肝损伤中的临床应用争议与研究进展[J/OL]. 西北药学杂志, 2026: 1-15.
https://link.cnki.net/urlid/61.1108.R.20260114.1647.002, 2026-01-15.
[10] 陈科婷, 周明. 糖皮质激素预防性使用条件下分化综合征的临床特征及高危因素[J]. 湖南师范大学学报(医学版), 2022, 19(6): 75-78.
[11] 王潇, 张静. 糖皮质激素在社区获得性肺炎中的临床价值: 循证医学视角下的争议与共识[J]. 实用医院临床杂志, 2025, 22(6): 22-26.
[12] Ziswiler, R., Steinmann-Niggli, K., Kappeler, A., Daniel, C. and Marti, H.P. (1998) Mycophenolic Acid: A New Approach to the Therapy of Experimental Mesangial Proliferative Glomerulonephritis. Journal of the American Society of Nephrology, 9, 2055-2066. [Google Scholar] [CrossRef] [PubMed]
[13] Tang, S., Leung, J., Chan, L., Lui, Y., Tang, C., Ho, Y., et al. (2005) Mycophenolate Mofetil Alleviates Persistent Proteinuria in IgA Nephropathy. Hong Kong Journal of Nephrology, 7, A5. [Google Scholar] [CrossRef] 
[14] 关米洁, 何永成, 李彤, 等. 霉酚酸酯对IgA肾病患者血清和尿液sTfR水平的影响[J]. 中国中西医结合肾病杂志, 2016, 17(5): 414-418.
[15] Beckwith, H., Medjeral-Thomas, N., Galliford, J., Griffith, M., Levy, J., Lightstone, L., et al. (2017) Mycophenolate Mofetil Therapy in Immunoglobulin a Nephropathy: Histological Changes after Treatment. Nephrology Dialysis Transplantation, 32, i123-i128. [Google Scholar] [CrossRef] [PubMed]
[16] 杜培玮, 文煜冰, 陈朝英, 等. 不同年龄段过敏性紫癜性肾炎患儿接受霉酚酸酯或环磷酰胺治疗的疗效差异分析[J]. 中国当代儿科杂志, 2023, 25(11): 1113-1117.
[17] 唐飞, 陶彩, 万启军. 霉酚酸酯治疗IgA肾病的研究近况[J]. 中国中西医结合肾病杂志, 2019, 20(1): 87-89.
[18] Yuan, D., Fang, Z., Sun, F., Chang, J., Teng, J., Lin, S., et al. (2017) Effect of Vitamin D and Tacrolimus Combination Therapy on Iga Nephropathy. Medical Science Monitor, 23, 3170-3177. [Google Scholar] [CrossRef] [PubMed]
[19] 付玉杰, 李静, 马毅, 等. 新型钙调神经磷酸酶抑制剂——伏环孢素[J]. 临床药物治疗杂志, 2024, 22(8): 17-21.
[20] 黄铁花, 张韶辉, 李璐璐, 等. 环孢素A治疗免疫球蛋白A肾病患者的临床研究[J]. 中国临床药理学杂志, 2020, 36(20): 3212-3215.
[21] 卢发菊, 陈永建, 杨磊. 环孢素A干预IgA肾病进展的研究[J]. 临床肾脏病杂志, 2016, 16(10): 621-624.
[22] 韩聪, 高冉冉, 陈怡冰, 等. 黄芪-丹参调控线粒体生物发生改善环孢素A慢性肾毒性[J]. 中华中医药杂志, 2025, 40(5): 2608-2613.
[23] 刘瑶, 李伟. 中西医结合防治环孢素A不良反应的思路与方法[J]. 中华中医药学刊, 2019, 37(11): 2645-2648.
[24] 仓怀芹, 初向华, 董加花, 等. 环孢素联合伏立康唑致儿童高血压及神经系统毒性1例[J]. 药物流行病学杂志, 2020, 29(3): 212-214.
[25] 王欣茹, 郭兆安. 钙调磷酸酶抑制剂引起骨质疏松分析[J]. 中国骨质疏松杂志, 2025, 31(5): 760-764.
[26] Medjeral-Thomas, N.R., Cook, H.T. and Pickering, M.C. (2021) Complement Activation in Iga Nephropathy. Seminars in Immunopathology, 43, 679-690. [Google Scholar] [CrossRef] [PubMed]
[27] Zhang, H., Rizk, D.V., Perkovic, V., Maes, B., Kashihara, N., Rovin, B., et al. (2024) Results of a Randomized Double-Blind Placebo-Controlled Phase 2 Study Propose Iptacopan as an Alternative Complement Pathway Inhibitor for IgA Nephropathy. Kidney International, 105, 189-199. [Google Scholar] [CrossRef] [PubMed]
[28] Perkovic, V., Barratt, J., Rovin, B., Kashihara, N., Maes, B., Zhang, H., et al. (2025) Alternative Complement Pathway Inhibition with Iptacopan in Iga Nephropathy. New England Journal of Medicine, 392, 531-543. [Google Scholar] [CrossRef] [PubMed]
[29] Langereis, J.D., van den Broek, B., Franssen, S., Joosten, I., Blijlevens, N.M.A., de Jonge, M.I., et al. (2020) Eculizumab Impairs Neisseria Meningitidis Serogroup B Killing in Whole Blood despite 4CMenB Vaccination of PNH Patients. Blood Advances, 4, 3615-3620. [Google Scholar] [CrossRef] [PubMed]
[30] Popova, A., Slisere, B., Racenis, K., Kuzema, V., Karklins, R., Saulite, M., et al. (2024) IgA Class-Switched CD27-CD21+ B Cells in IgA Nephropathy. Nephrology Dialysis Transplantation, 40, 505-515. [Google Scholar] [CrossRef] [PubMed]
[31] Cheung, C.K., Barratt, J., Liew, A., Zhang, H., Tesar, V. and Lafayette, R. (2024) The Role of BAFF and APRIL in IgA Nephropathy: Pathogenic Mechanisms and Targeted Therapies. Frontiers in Nephrology, 3, Article ID: 1346769. [Google Scholar] [CrossRef] [PubMed]
[32] 赵颖, 张丽洁, 马爽, 等. 利妥昔单抗治疗原发性IgA肾病的疗效及安全性分析[J]. 实用药物与临床, 2023, 26(6): 516-521.
[33] 雷文晖, 金烈. 小剂量利妥昔单抗治疗激素依赖的IgA肾病1例[J]. 浙江实用医学, 2020, 25(5): 378-379.
[34] Lafayette, R.A., Canetta, P.A., Rovin, B.H., Appel, G.B., Novak, J., Nath, K.A., et al. (2016) A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. Journal of the American Society of Nephrology, 28, 1306-1313. [Google Scholar] [CrossRef] [PubMed]
[35] Lydia, R. and Jonathan, B. (2025) Targeting B Cells in IgA Nephropathy: From Pathogenic Insight to Therapeutic Horizon. Clinical Kidney Journal, 18, ii26-ii34.
[36] Zeng, L., Yang, K., Wu, Y., Yu, G., Yan, Y., Hao, M., et al. (2024) Telitacicept: A Novel Horizon in Targeting Autoimmunity and Rheumatic Diseases. Journal of Autoimmunity, 148, Article ID: 103291. [Google Scholar] [CrossRef] [PubMed]
[37] Xie, J., Fan, X., Su, Y., Zhou, H., Cao, S., Zhu, X., et al. (2022) Pharmacokinetic Characteristics, Safety, and Tolerability of Telitacicept, an Injectable Recombinant Human B‐Lymphocyte Stimulating Factor Receptor‐Antibody Fusion Protein, in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development, 11, 1273-1283. [Google Scholar] [CrossRef] [PubMed]
[38] 宋江曼, 孙雪林, 许喆, 等. 泰它西普在IgA肾病中的疗效及安全性研究进展[J]. 协和医学杂志, 2025, 16(6): 1413-1418.
[39] 张新颖. 泰它西普治疗原发性IgA肾病的有效性及安全性分析[J]. 实用药物与临床, 2025, 28(8): 584-587.
[40] 董寅迪, 吴歌, 李冠华. 泰它西普治疗IgA肾病的有效性及安全性分析[J]. 实用临床医药杂志, 2023, 27(10): 62-66.
[41] 朱丽君, 陈沛, 吕继成. 泰它西普治疗IgA肾病的有效性及安全性研究[J]. 中国血液净化, 2025, 24(4): 283-287.
[42] 杨佳, 高洁, 赵文静, 等. 泰它西普在IgA肾病和狼疮性肾炎中的研究进展[J]. 中国现代医学杂志, 2022, 32(19): 51-56.
[43] Rovin, B.H., Adler, S.G., Barratt, J., Bridoux, F., Burdge, K.A., Chan, T.M., et al. (2021) Executive Summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney International, 100, 753-779. [Google Scholar] [CrossRef] [PubMed]
[44] Lv, J., Zhang, H., Wong, M.G., Jardine, M.J., Hladunewich, M., Jha, V., et al. (2017) Effect of Oral Methylprednisolone on Clinical Outcomes in Patients with IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA, 318, 432-442. [Google Scholar] [CrossRef] [PubMed]
[45] Du, W., Chen, Z., Fang, Z., Li, J., Weng, Q., Zheng, Q., et al. (2023) Oral Glucocorticoids with Intravenous Cyclophosphamide or Oral Glucocorticoids Alone in the Treatment of IgA Nephropathy Present with Nephrotic Syndrome and Mesangioproliferative Glomerulonephritis. Clinical Kidney Journal, 16, 2567-2577. [Google Scholar] [CrossRef] [PubMed]
[46] Chen, N., Huang, H. and Yang, Y. (2021) Long-Term Effects of Immunosuppression Treatment on IgA Nephropathy: A Systematic Review and Meta-Analysis. Annals of Palliative Medicine, 10, 11830-11839. [Google Scholar] [CrossRef] [PubMed]
[47] Chen, Y., Li, Y., Yang, S., Li, Y. and Liang, M. (2014) Efficacy and Safety of Mycophenolate Mofetil Treatment in IgA Nephropathy: A Systematic Review. BMC Nephrology, 15, Article No. 193. [Google Scholar] [CrossRef] [PubMed]